ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
07 Apr, 2025
RNA researcher Anastasia Khvorova, PhD, a professor of RNA therapeutics at UMass Chan Medical School, will receive the 2025 Else Kröner Fresenius Prize for Medical Research on May 15, 2025. The award ceremony will take place at the Städel Museum in Frankfurt am Main as part of a celebration with Fresenius SE & Co. KGaA marking the 100th birthday of Else Kröner.
The Else Kröner-Fresenius-Stiftung (EKFS) is honoring Khvorova for her groundbreaking work in RNA-based therapies. Her research plays a crucial role in developing new treatments for genetic and neurodegenerative diseases, including Huntington's disease. The Else Kröner Fresenius Prize, valued at 2.5 million euros, is one of the largest research prizes globally.
The event will also celebrate the legacy of Else Kröner alongside Khvorova's achievements. Media representatives are invited to attend the award ceremony, with registration required by May 10 at b.jerke@ekfs.de for the closed event. For those wishing to meet Khvorova before the ceremony, meetings can be arranged.
Khvorova, who leads a multidisciplinary research team at UMass Chan Medical School, focuses on developing RNA molecules to enhance their effectiveness in treating diseases. Her work aims to improve the delivery, stability, efficacy, and specificity of RNA therapeutics, with a particular emphasis on enabling these molecules to reach organs beyond the liver, including the brain and other vital organs.
Khvorova intends to use the prize money to develop RNA molecules that prevent the production of toxic proteins in the brain, addressing diseases like Huntington's. This genetic, neurodegenerative disease causes progressive movement disorders and other severe symptoms, often beginning in mid-adulthood.
Khvorova's career spans over two decades in oligonucleotide-based drug development. She has contributed significantly to the field with over 150 patents and is an elected fellow of the National Academy of Inventors. She has been a professor at UMass Chan Medical School since 2012.